CA3215792A1 - Processes for the synthesis of valbenazine - Google Patents

Processes for the synthesis of valbenazine Download PDF

Info

Publication number
CA3215792A1
CA3215792A1 CA3215792A CA3215792A CA3215792A1 CA 3215792 A1 CA3215792 A1 CA 3215792A1 CA 3215792 A CA3215792 A CA 3215792A CA 3215792 A CA3215792 A CA 3215792A CA 3215792 A1 CA3215792 A1 CA 3215792A1
Authority
CA
Canada
Prior art keywords
formula
compound
reacting
afford
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215792A
Other languages
English (en)
French (fr)
Inventor
John Lloyd Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3215792A1 publication Critical patent/CA3215792A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3215792A 2021-04-26 2022-04-25 Processes for the synthesis of valbenazine Pending CA3215792A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163180043P 2021-04-26 2021-04-26
US63/180,043 2021-04-26
US202163286764P 2021-12-07 2021-12-07
US63/286,764 2021-12-07
PCT/US2022/026208 WO2022232060A1 (en) 2021-04-26 2022-04-25 Processes for the synthesis of valbenazine

Publications (1)

Publication Number Publication Date
CA3215792A1 true CA3215792A1 (en) 2022-11-03

Family

ID=81654703

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215792A Pending CA3215792A1 (en) 2021-04-26 2022-04-25 Processes for the synthesis of valbenazine

Country Status (6)

Country Link
US (1) US20240239791A1 (https=)
EP (1) EP4330255A1 (https=)
JP (1) JP2024516199A (https=)
CA (1) CA3215792A1 (https=)
IL (1) IL307826A (https=)
WO (1) WO2022232060A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) * 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
CA3150961A1 (en) * 2019-09-13 2021-03-18 John Tucker Processes for the synthesis of valbenazine

Also Published As

Publication number Publication date
US20240239791A1 (en) 2024-07-18
WO2022232060A1 (en) 2022-11-03
EP4330255A1 (en) 2024-03-06
JP2024516199A (ja) 2024-04-12
IL307826A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
BG61323B2 (bg) Производни на пиперидина,тяхното получаване и използването им като лекарства
EP1919893A2 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
CN1303283A (zh) 噻吩基吡咯基烷氧基乙胺,它们的制备以及它们作为药物的应用
WO2011140328A1 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
AU2018371771A1 (en) Solid state form of Valbenazine
EP2103612A1 (en) Crystalline forms of palonosetron hydrochloride
AU2011334928A1 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
JPH10504820A (ja) Ｎ−置換されたフェノチアジン類の使用
WO2012017028A1 (en) A novel crystalline compound comprising saxagliptin and phosphoric acid
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
JPWO1994001392A1 (ja) （−）−リトドリン
CA3215792A1 (en) Processes for the synthesis of valbenazine
JPWO2003033507A1 (ja) ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
FR2883285A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
JP2012521417A (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
EP2362870A2 (en) Novel processes and pure polymorphs
WO2019167068A1 (en) Novel polymorphs of ribociclib succinate
EP2102195A1 (en) Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl]-pyrrole-2, 5-d ione
WO2006023676A1 (en) Clopidogrel napsylate salt
KR20140022851A (ko) 오타믹사반의 벤조산염
CN117480170A (zh) 用于合成缬苯那嗪的方法
HK40107951A (zh) 用於合成缬苯那嗪的方法
EP1674468A1 (en) Polymorphs of clopidogrel hydrobromide

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260417

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260423

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260423